Vertex Pharmaceuticals (VRTX) Q1 FY25 earnings call

Earnings call· Mar 2025 (Q1 FY25)· Health Care· May 5, 2025

Source: earnings call transcript

Vertex Pharmaceuticals delivered a strong Q1 FY25, marked by continued revenue growth and significant progress across its diversified portfolio. The company is executing on multiple launches, including ALYFTREK and JOURNAVX, while advancing a robust pipeline with five programs in pivotal development. Management remains focused on expanding patient access and driving innovation, despite some isolated ex-U.S. revenue headwinds and a temporary pause in one early-stage CF program.

You’re reading a preview. Opening the full call uses 1 concall credit.

VRTX operating KPIs by quarter

VRTX operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Jun 2025 Q2 FY25	Sep 2025 Q3 FY25	Dec 2025 Q4 FY25	Change vs prior quarter
Patients CASGEVY	16 And finally, a total of 29 patients have completed their treatment journey and received their infusions of CASGEVY edited cells, including 16 patients in the second quarter of 2025. Source: earnings call transcript	10 And a total of 39 patients have received their infusions of CASGEVY edited cells, including 10 patients in the third quarter of 2025. Source: earnings call transcript	30 You can see the evidence of this acceleration in our excellent quarter 4 '25 results, where CASGEVY had 111 new patient initiations, 37 patients with first cell collections and 30 patients receiving infusions, driving $54 million in quarterly revenue. Source: earnings call transcript	+200%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.